Diagnostic accuracy of urine AlereLAM and FujiLAM assays for diagnosing active tuberculosis in people living with HIV: a systematic review and meta-analysis
Journal of Associated Medical Sciences · 23.06.2026 · 59 (3) · 151-167
DOI: 10.66285/jams.2026.089 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Journal of Associated Medical Sciences, online erschienen am 23.06.2026. Verfasst von Andiesta Asriyah Mariam Saman und 3 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
People living with HIV (PLHIV) remain at high risk of active tuberculosis (TB), yet diagnosis is often challenging due to difficulty obtaining sputum and reduced sensitivity of conventional tests. Urine-based lipoarabinomannan (LAM) assays offer a rapid, non-sputum diagnostic approach. The more recent Fujifilm SILVAMP TB LAM (FujiLAM) may provide better diagnostic performance than the extensively used Alere Determine TB-LAM (AlereLAM).
Objectives
To evaluate the diagnostic accuracy of urine AlereLAM and FujiLAM for diagnosing active TB in PLHIV, and to compare the pooled diagnostic performance of AlereLAM versus FujiLAM.
Methods
We conducted a systematic review and a meta-analysis of diagnostic test accuracy in accordance with PRISMA-DTA guidelines. PubMed, Scopus, and SpringerLink were searched for studies published between 2016 and 2025. Eligible studies enrolled PLHIV evaluated for suspected active TB and assessed urine AlereLAM and/or FujiLAM against microbiological reference standards (MRS) and/or composite reference standards (CRS), with MRS prioritized. Diagnostic 2×2 data were extracted or reconstructed. Pooled sensitivity, specificity, likelihood ratios, and diagnostic odds ratios were estimated using a bivariate random-effects model, with separate analyses for AlereLAM and FujiLAM.
Results
Twenty-five diagnostic accuracy studies were included. AlereLAM demonstrated a pooled sensitivity of 0.364 (95% CI 0.272-0.467) and specificity of 0.928 (95% CI 0.875-0.960). In contrast, FujiLAM showed a substantially higher pooled sensitivity of 0.642 (95% CI 0.567-0.711) while maintaining a high specificity of 0.901 (95% CI 0.872-0.924). FujiLAM yielded a higher diagnostic odds ratio (16.34 vs 7.38), a higher positive likelihood ratio (6.49 vs 5.06), and a lower negative likelihood ratio (0.40 vs 0.69) than AlereLAM. Summary receiver operating characteristic (SROC) analyses demonstrated superior overall diagnostic accuracy for FujiLAM.
Conclusion
Urine FujiLAM showed markedly higher sensitivity than AlereLAM while maintaining high specificity for diagnosing active TB in PLHIV. These findings suggest that next-generation urine LAM assays may substantially improve TB case detection in this high-risk population, particularly in settings where sputum-based diagnostics are limited.
Zitieren
APA
Saman, A. A. M., Wardhani, P., Aryati, & Rahman, L. N. (2026). Diagnostic accuracy of urine AlereLAM and FujiLAM assays for diagnosing active tuberculosis in people living with HIV: a systematic review and meta-analysis. Journal of Associated Medical Sciences, 59(3), 151-167. https://doi.org/10.66285/jams.2026.089
Vancouver
Saman AAM, Wardhani P, Aryati, Rahman LN. Diagnostic accuracy of urine AlereLAM and FujiLAM assays for diagnosing active tuberculosis in people living with HIV: a systematic review and meta-analysis. Journal of Associated Medical Sciences. 2026;59(3):151-167. doi:10.66285/jams.2026.089
BibTeX
@article{Saman2026,
author = {Saman, Andiesta Asriyah Mariam and Wardhani, Puspa and Aryati and Rahman, Lukman Nur},
title = {Diagnostic accuracy of urine AlereLAM and FujiLAM assays for diagnosing active tuberculosis in people living with HIV: a systematic review and meta-analysis},
journal = {Journal of Associated Medical Sciences},
year = {2026},
volume = {59},
number = {3},
pages = {151--167},
doi = {10.66285/jams.2026.089}
}
EUVIMED